JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) 3-Year EBITDA Growth Rate : 50.90% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is JW (Cayman) Therapeutics Co 3-Year EBITDA Growth Rate?

JW (Cayman) Therapeutics Co's EBITDA per Share for the six months ended in Dec. 2023 was $0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was 50.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -6.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of JW (Cayman) Therapeutics Co was 50.90% per year. The lowest was -35.70% per year. And the median was -4.10% per year.

Competitive Comparison of JW (Cayman) Therapeutics Co's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

JW (Cayman) Therapeutics Co's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where JW (Cayman) Therapeutics Co's 3-Year EBITDA Growth Rate falls into.

JW (Cayman) Therapeutics Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

JW (Cayman) Therapeutics Co (OTCPK:JWCTF) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

JW (Cayman) Therapeutics Co 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (OTCPK:JWCTF) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

02126:Hong Kong

Address

No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN

Website

https://www.jwtherapeutics.com

JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.

JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Headlines

No Headlines